Registry-listed formulations

This catalogue entry has no confirmed scientific concept.

Each study is counted once in the molecule profile. Registry products remain separate. Naming an ingredient does not establish that products are interchangeable or what participants received.

0 source entries across 0 studies. This list may not include all unresolved or historical entries.

    Success Metrics

    Clinical Success Rate
    100.0%

    Based on 3 completed trials

    Completion Rate
    100%(3/3)
    Active Trials
    0(0%)
    Results Posted
    33%(1 trials)

    Phase Distribution

    Phase 3
    3
    100%

    Phase Distribution

    0

    Early Stage

    0

    Mid Stage

    3

    Late Stage

    Phase Distribution3 total trials
    Phase 3Large-scale testing
    3(100.0%)

    Highest Phase Reached

    Phase 3

    Trial Status & Enrollment

    Completion Rate

    100.0%

    3 of 3 finished

    Non-Completion Rate

    0.0%

    0 ended early

    Currently Active

    0

    trials recruiting

    Total Trials

    3

    all time

    Status Distribution
    Completed(3)

    Detailed Status

    Completed3

    Development Timeline

    Analytics

    Development Status

    Total Trials
    3
    Active
    0
    Success Rate
    100.0%
    Most Advanced
    Phase 3

    Trials by Phase

    Phase 33 (100.0%)

    Trials by Status

    completed3100%

    Recent Activity

    0 active trials
    Showing 3 of 3
    completedphase_3

    Safety and Efficacy of Intravenous Immunoglobulin IgPro10 in Patients With Primary Immunodeficiencies (PID)

    NCT00322556
    completedphase_3

    Efficacy and Safety of Intravenous Immunoglobulin IgPro10 in Patients With Primary Immunodeficiencies (PID)

    NCT00168025
    completedphase_3

    Efficacy and Safety of Intravenous Immunoglobulin IVIG-F10 in Patients With Primary Immunodeficiencies (PID)

    NCT00168012

    Clinical Trials (3)

    Showing 3 of 3 trials
    NCT00322556Phase 3

    Safety and Efficacy of Intravenous Immunoglobulin IgPro10 in Patients With Primary Immunodeficiencies (PID)

    Completed
    NCT00168025Phase 3

    Efficacy and Safety of Intravenous Immunoglobulin IgPro10 in Patients With Primary Immunodeficiencies (PID)

    Completed
    NCT00168012Phase 3

    Efficacy and Safety of Intravenous Immunoglobulin IVIG-F10 in Patients With Primary Immunodeficiencies (PID)

    Completed

    All 3 trials loaded

    Drug Details

    Intervention Type
    Drug
    Total Trials
    3